Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 9 studies | 25% ± 7% | |
epithelial cell | 7 studies | 30% ± 11% | |
fibroblast | 5 studies | 20% ± 5% | |
astrocyte | 5 studies | 21% ± 4% | |
natural killer cell | 4 studies | 18% ± 3% | |
glutamatergic neuron | 4 studies | 37% ± 14% | |
macrophage | 4 studies | 21% ± 2% | |
hematopoietic precursor cell | 3 studies | 20% ± 3% | |
microglial cell | 3 studies | 23% ± 1% | |
basal cell | 3 studies | 28% ± 9% | |
lymphocyte | 3 studies | 21% ± 2% | |
GABAergic neuron | 3 studies | 38% ± 7% | |
oligodendrocyte precursor cell | 3 studies | 25% ± 7% | |
dendritic cell | 3 studies | 22% ± 5% | |
abnormal cell | 3 studies | 30% ± 9% | |
T cell | 3 studies | 16% ± 0% | |
endothelial cell of lymphatic vessel | 3 studies | 20% ± 3% | |
pericyte | 3 studies | 20% ± 5% | |
transit amplifying cell | 3 studies | 38% ± 14% | |
goblet cell | 3 studies | 19% ± 2% | |
interneuron | 3 studies | 34% ± 19% | |
neuron | 3 studies | 25% ± 4% | |
erythroblast | 3 studies | 27% ± 6% | |
oligodendrocyte | 3 studies | 20% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 7579.02 | 1445 / 1445 | 100% | 72.30 | 183 / 183 |
lung | 100% | 6436.81 | 578 / 578 | 100% | 53.61 | 1155 / 1155 |
stomach | 100% | 4849.83 | 359 / 359 | 100% | 59.44 | 286 / 286 |
breast | 100% | 8080.57 | 459 / 459 | 100% | 55.35 | 1116 / 1118 |
intestine | 100% | 6252.02 | 966 / 966 | 100% | 61.86 | 526 / 527 |
skin | 100% | 11951.81 | 1809 / 1809 | 100% | 63.95 | 471 / 472 |
uterus | 100% | 8534.69 | 170 / 170 | 100% | 59.90 | 458 / 459 |
ovary | 100% | 10188.76 | 180 / 180 | 100% | 46.37 | 429 / 430 |
bladder | 100% | 7417.33 | 21 / 21 | 100% | 57.29 | 502 / 504 |
thymus | 100% | 7477.90 | 653 / 653 | 100% | 46.89 | 602 / 605 |
prostate | 100% | 6548.51 | 245 / 245 | 99% | 37.09 | 499 / 502 |
brain | 99% | 4484.02 | 2605 / 2642 | 100% | 51.52 | 705 / 705 |
kidney | 100% | 4906.28 | 89 / 89 | 98% | 38.29 | 884 / 901 |
pancreas | 99% | 3956.56 | 324 / 328 | 99% | 39.87 | 176 / 178 |
adrenal gland | 100% | 6596.24 | 258 / 258 | 96% | 32.25 | 220 / 230 |
liver | 100% | 3289.55 | 225 / 226 | 90% | 21.24 | 367 / 406 |
adipose | 100% | 7164.14 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 46.98 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 63.12 | 29 / 29 |
muscle | 100% | 5792.58 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 7841.00 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 59.09 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 30.31 | 1 / 1 |
blood vessel | 100% | 5422.30 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 97% | 4675.31 | 839 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 89% | 6086.98 | 828 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042177 | Biological process | negative regulation of protein catabolic process |
GO_0006282 | Biological process | regulation of DNA repair |
GO_1903241 | Biological process | U2-type prespliceosome assembly |
GO_0000398 | Biological process | mRNA splicing, via spliceosome |
GO_0008380 | Biological process | RNA splicing |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0043484 | Biological process | regulation of RNA splicing |
GO_0000375 | Biological process | RNA splicing, via transesterification reactions |
GO_0005686 | Cellular component | U2 snRNP |
GO_0005730 | Cellular component | nucleolus |
GO_0005681 | Cellular component | spliceosomal complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0071005 | Cellular component | U2-type precatalytic spliceosome |
GO_0005684 | Cellular component | U2-type spliceosomal complex |
GO_0000124 | Cellular component | SAGA complex |
GO_0071013 | Cellular component | catalytic step 2 spliceosome |
GO_0005689 | Cellular component | U12-type spliceosomal complex |
GO_0005634 | Cellular component | nucleus |
GO_0044877 | Molecular function | protein-containing complex binding |
GO_0030620 | Molecular function | U2 snRNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | SF3B3 |
Protein name | Splicing factor 3B subunit 3 (Pre-mRNA-splicing factor SF3b 130 kDa subunit) (SF3b130) (STAF130) (Spliceosome-associated protein 130) (SAP 130) Splicing factor 3b subunit 3 |
Synonyms | KIAA0017 SAP130 |
Description | FUNCTION: Component of the 17S U2 SnRNP complex of the spliceosome, a large ribonucleoprotein complex that removes introns from transcribed pre-mRNAs . The 17S U2 SnRNP complex (1) directly participates in early spliceosome assembly and (2) mediates recognition of the intron branch site during pre-mRNA splicing by promoting the selection of the pre-mRNA branch-site adenosine, the nucleophile for the first step of splicing . Within the 17S U2 SnRNP complex, SF3B3 is part of the SF3B subcomplex, which is required for 'A' complex assembly formed by the stable binding of U2 snRNP to the branchpoint sequence in pre-mRNA . Sequence independent binding of SF3A and SF3B subcomplexes upstream of the branch site is essential, it may anchor U2 snRNP to the pre-mRNA . May also be involved in the assembly of the 'E' complex . Also acts as a component of the minor spliceosome, which is involved in the splicing of U12-type introns in pre-mRNAs . . |
Accessions | H3BMB0 J3QRB2 Q15393 I3L4G7 ENST00000567654.1 ENST00000302516.10 [Q15393-1] J3QL37 ENST00000566095.6 ENST00000567635.5 ENST00000577085.1 J3QKV4 ENST00000569687.1 |